COCAINE

First marketed in 1860

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C17H21NO4
Molecular Weight	303.3529
Optical Activity	UNSPECIFIED
Defined Stereocenters	4 / 4
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

COC(=O)[C@@H]1[C@H]2CC[C@@H](C[C@@H]1OC(=O)C3=CC=CC=C3)N2C

InChI

InChIKey=ZPUCINDJVBIVPJ-LJISPDSOSA-N

InChI=1S/C17H21NO4/c1-18-12-8-9-13(18)15(17(20)21-2)14(10-12)22-16(19)11-6-4-3-5-7-11/h3-7,12-15H,8-10H2,1-2H3/t12-,13+,14-,15+/m0/s1

HIDE SMILES / InChI

Molecular Formula	C17H21NO4
Molecular Weight	303.3529
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	4 / 4
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.drugbank.ca/drugs/DB00907
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/11895133 | https://www.ncbi.nlm.nih.gov/pubmed/12067559 | https://www.ncbi.nlm.nih.gov/pubmed/17255098 | https://www.ncbi.nlm.nih.gov/pubmed/19897082

Cocaine is an alkaloid ester extracted from the leaves of plants including coca. Cocaine is a local anesthetic and vasoconstrictor and is clinically used for that purpose, particularly in the eye, ear, nose, and throat. It also has powerful central nervous system effects similar to the amphetamines and is a drug of abuse. Cocaine, like amphetamines, acts by multiple mechanisms on brain catecholaminergic neurons; the mechanism of its reinforcing effects is thought to involve inhibition of dopamine uptake. Cocaine is addictive due to its effect on the reward pathway in the brain. After a short period of use, there is a high risk that dependence will occur. Its use also increases the risk of stroke, myocardial infarction, lung problems in those who smoke it, blood infections, and sudden cardiac death. Cocaine sold on the street is commonly mixed with local anesthetics, cornstarch, quinine, or sugar which can result in additional toxicity. Following repeated doses, a person may have decreased the ability to feel pleasure and be very physically tired. Cocaine acts by inhibiting the reuptake of serotonin, norepinephrine, and dopamine. This results in greater concentrations of these three neurotransmitters in the brain. It can easily cross the blood-brain barrier and may lead to the breakdown of the barrier.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Serotonin transporter 172 Target ID: CHEMBL313 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12067559	Inhibitor 8146	155.0 nM [Ki]
Norepinephrine transporter 183 Target ID: CHEMBL304 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12067559	Inhibitor 8146	108.0 nM [Ki]
Dopamine transporter 172 Target ID: CHEMBL338 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12067559	Inhibitor 8146	274.0 nM [Ki]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Cocaine-related disorders 15 Sources: https://clinicaltrials.gov/ct2/show/NCT00000270	Primary		Phase IV 63	Cocaine Approved Use INDICATIONS AND USAGE. Cocaine hydrochloride topical solution is indicated for the introduction of local (topical) anesthesia of accessible mucous membranes of the oral, laryngeal and nasal cavities.
Procedures and surgeries on or through accessible mucous membranes of the nasal cavities 4 Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=24faa247-fe12-4574-881d-445b078b3e87	Primary		Approved 8307	Cocaine Approved Use INDICATIONS AND USAGE. Cocaine hydrochloride topical solution is indicated for the introduction of local (topical) anesthesia of accessible mucous membranes of the oral, laryngeal and nasal cavities.

C_max

Value	Dose	Co-administered	Analyte	Population
550 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7242115/	100 mg single, intravenous dose: 100 mg route of administration: Intravenous experiment type: SINGLE co-administered:		COCAINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
840 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7242115/	100 mg single, intravenous dose: 100 mg route of administration: Intravenous experiment type: SINGLE co-administered:		COCAINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
78.9 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7242115/	100 mg single, intravenous dose: 100 mg route of administration: Intravenous experiment type: SINGLE co-administered:		COCAINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
25 mg single, intravenous Dose: 25 mg Route: intravenous Route: single Dose: 25 mg Sources: https://pubmed.ncbi.nlm.nih.gov/8926741	healthy, 30-43 years n = 6 Health Status: healthy Age Group: 30-43 years Sex: M Population Size: 6 Sources: https://pubmed.ncbi.nlm.nih.gov/8926741	Sources: https://pubmed.ncbi.nlm.nih.gov/8926741
32 mg single, intranasal Dose: 32 mg Route: intranasal Route: single Dose: 32 mg Sources: https://pubmed.ncbi.nlm.nih.gov/8926741	healthy, 30-43 years n = 6 Health Status: healthy Age Group: 30-43 years Sex: M Population Size: 6 Sources: https://pubmed.ncbi.nlm.nih.gov/8926741	Sources: https://pubmed.ncbi.nlm.nih.gov/8926741
42 mg single, respiratory Dose: 42 mg Route: respiratory Route: single Dose: 42 mg Sources: https://pubmed.ncbi.nlm.nih.gov/8926741	healthy, 30-43 years n = 6 Health Status: healthy Age Group: 30-43 years Sex: M Population Size: 6 Sources: https://pubmed.ncbi.nlm.nih.gov/8926741	Sources: https://pubmed.ncbi.nlm.nih.gov/8926741
8 % single, intranasal Highest studied dose Dose: 8 % Route: intranasal Route: single Dose: 8 % Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209963Orig1s000MedR.pdf Page: p. 56, 74	unhealthy, 45 years (range: 17- 83 years) n = 275 Health Status: unhealthy Age Group: 45 years (range: 17- 83 years) Sex: M+F Population Size: 275 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209963Orig1s000MedR.pdf Page: p. 56, 74	Other AEs: Headache, Epistaxis... Other AEs: Headache (1.5%) Epistaxis (0.7%) Anxiety (0.7%) Foreign body sensation in eyes (0.4%) Facial pain (0.4%) Neck pain (0.4%) Dizziness (0.4%) Nasal congestion (0.4%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209963Orig1s000MedR.pdf Page: p. 56, 74
2 g single, oral Overdose Dose: 2 g Route: oral Route: single Dose: 2 g Sources: https://pubmed.ncbi.nlm.nih.gov/4443787	unhealthy, adult n = 1 Health Status: unhealthy Age Group: adult Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/4443787	Other AEs: Adverse event... Other AEs: Adverse event (grade 5) Sources: https://pubmed.ncbi.nlm.nih.gov/4443787
160 mg single, intranasal Recommended Dose: 160 mg Route: intranasal Route: single Dose: 160 mg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209963lbl.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209963lbl.pdf	Other AEs: Drug abuse... Other AEs: Drug abuse Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209963lbl.pdf

AEs

AE	Significance	Dose	Population
Dizziness	0.4%	8 % single, intranasal Highest studied dose Dose: 8 % Route: intranasal Route: single Dose: 8 % Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209963Orig1s000MedR.pdf Page: p. 56, 74	unhealthy, 45 years (range: 17- 83 years) n = 275 Health Status: unhealthy Age Group: 45 years (range: 17- 83 years) Sex: M+F Population Size: 275 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209963Orig1s000MedR.pdf Page: p. 56, 74
Facial pain	0.4%	8 % single, intranasal Highest studied dose Dose: 8 % Route: intranasal Route: single Dose: 8 % Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209963Orig1s000MedR.pdf Page: p. 56, 74	unhealthy, 45 years (range: 17- 83 years) n = 275 Health Status: unhealthy Age Group: 45 years (range: 17- 83 years) Sex: M+F Population Size: 275 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209963Orig1s000MedR.pdf Page: p. 56, 74
Foreign body sensation in eyes	0.4%	8 % single, intranasal Highest studied dose Dose: 8 % Route: intranasal Route: single Dose: 8 % Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209963Orig1s000MedR.pdf Page: p. 56, 74	unhealthy, 45 years (range: 17- 83 years) n = 275 Health Status: unhealthy Age Group: 45 years (range: 17- 83 years) Sex: M+F Population Size: 275 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209963Orig1s000MedR.pdf Page: p. 56, 74
Nasal congestion	0.4%	8 % single, intranasal Highest studied dose Dose: 8 % Route: intranasal Route: single Dose: 8 % Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209963Orig1s000MedR.pdf Page: p. 56, 74	unhealthy, 45 years (range: 17- 83 years) n = 275 Health Status: unhealthy Age Group: 45 years (range: 17- 83 years) Sex: M+F Population Size: 275 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209963Orig1s000MedR.pdf Page: p. 56, 74
Neck pain	0.4%	8 % single, intranasal Highest studied dose Dose: 8 % Route: intranasal Route: single Dose: 8 % Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209963Orig1s000MedR.pdf Page: p. 56, 74	unhealthy, 45 years (range: 17- 83 years) n = 275 Health Status: unhealthy Age Group: 45 years (range: 17- 83 years) Sex: M+F Population Size: 275 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209963Orig1s000MedR.pdf Page: p. 56, 74
Anxiety	0.7%	8 % single, intranasal Highest studied dose Dose: 8 % Route: intranasal Route: single Dose: 8 % Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209963Orig1s000MedR.pdf Page: p. 56, 74	unhealthy, 45 years (range: 17- 83 years) n = 275 Health Status: unhealthy Age Group: 45 years (range: 17- 83 years) Sex: M+F Population Size: 275 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209963Orig1s000MedR.pdf Page: p. 56, 74
Epistaxis	0.7%	8 % single, intranasal Highest studied dose Dose: 8 % Route: intranasal Route: single Dose: 8 % Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209963Orig1s000MedR.pdf Page: p. 56, 74	unhealthy, 45 years (range: 17- 83 years) n = 275 Health Status: unhealthy Age Group: 45 years (range: 17- 83 years) Sex: M+F Population Size: 275 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209963Orig1s000MedR.pdf Page: p. 56, 74
Headache	1.5%	8 % single, intranasal Highest studied dose Dose: 8 % Route: intranasal Route: single Dose: 8 % Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209963Orig1s000MedR.pdf Page: p. 56, 74	unhealthy, 45 years (range: 17- 83 years) n = 275 Health Status: unhealthy Age Group: 45 years (range: 17- 83 years) Sex: M+F Population Size: 275 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209963Orig1s000MedR.pdf Page: p. 56, 74
Adverse event	grade 5	2 g single, oral Overdose Dose: 2 g Route: oral Route: single Dose: 2 g Sources: https://pubmed.ncbi.nlm.nih.gov/4443787	unhealthy, adult n = 1 Health Status: unhealthy Age Group: adult Sex: M Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/4443787
Drug abuse		160 mg single, intranasal Recommended Dose: 160 mg Route: intranasal Route: single Dose: 160 mg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209963lbl.pdf	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209963lbl.pdf

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1670	inhibitor 1695	inhibitor 1789	inhibitor 1570

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 1463 CYP2A6 670 CYP2B6 770 CYP2C8 869 CYP2C19 1410 CYP2E1 846 CYP3A4/5 261 P-gp 1401 BCRP 678 OAT1 584 OAT3 625 OATP1B1 770 OATP1B3 691 OCT2 630 OCT1 498 OCT3 143	CES2 24 P-gp 1491 BCRP 545 OAT1 314 OAT3 328 OATP1B1 389 OATP1B3 333 OCT2 336

Drug as perpetrator

Target	Modality	Activity	Clinical evidence
BCRP 751	inhibitor 3185 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209963Orig1s000ClinPharmR.pdf#page=28 Page: 28.0	no
CYP1A2 1620	inhibitor 3185 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209963Orig1s000ClinPharmR.pdf#page=27 Page: 27.0	no
CYP2A6 702	inhibitor 3185 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209963Orig1s000ClinPharmR.pdf#page=27 Page: 27.0	no
CYP2B6 946	inhibitor 3185 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209963Orig1s000ClinPharmR.pdf#page=27 Page: 27.0	no
CYP2C19 1484	inhibitor 3185 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209963Orig1s000ClinPharmR.pdf#page=27 Page: 27.0	no
CYP2C8 923	inhibitor 3185 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209963Orig1s000ClinPharmR.pdf#page=27 Page: 27.0	no
CYP2C9 1747	inhibitor 3185 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209963Orig1s000ClinPharmR.pdf#page=27 Page: 27.0	no
CYP2E1 929	inhibitor 3185 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209963Orig1s000ClinPharmR.pdf#page=27 Page: 27.0	no
CYP3A4/5 314	inhibitor 3185 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209963Orig1s000ClinPharmR.pdf#page=27 Page: 27.0	no
OAT1 588	inhibitor 3185 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209963Orig1s000ClinPharmR.pdf#page=27 Page: 27.0	no
OAT3 627	inhibitor 3185 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209963Orig1s000ClinPharmR.pdf#page=27 Page: 27.0	no
OATP1B1 785	inhibitor 3185 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209963Orig1s000ClinPharmR.pdf#page=27 Page: 27.0	no
OATP1B3 700	inhibitor 3185 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209963Orig1s000ClinPharmR.pdf#page=27 Page: 27.0	no
P-gp 1588	inhibitor 3185 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209963Orig1s000ClinPharmR.pdf#page=28 Page: 28.0	no
CYP2D6 1826	inhibitor 3185 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209963Orig1s000ClinPharmR.pdf#page=27 Page: 27.0	yes [IC50 1.2 uM]	unlikely (co-administration study) Comment: the relatively low plasma concentrations of cocaine resulting from therapeutic doses of GOPRELTO are not expected to raise significant drug-drug interaction concerns Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209963Orig1s000ClinPharmR.pdf#page=27 Page: 27.0
OCT2 631	inhibitor 3185 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209963Orig1s000ClinPharmR.pdf#page=27 Page: 27.0	yes [IC50 7.85 uM]	unlikely (co-administration study) Comment: the relatively low plasma concentrations of cocaine resulting from therapeutic doses of GOPRELTO are not expected to raise significant drug-drug interaction concerns Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209963Orig1s000ClinPharmR.pdf#page=27 Page: 27.0
OCT1 513	inhibitor 3185 Sources: https://pubmed.ncbi.nlm.nih.gov/16581093/	yes [Ki 85 uM]
OCT3 143	inhibitor 3185 Sources: https://pubmed.ncbi.nlm.nih.gov/16581093/	yes [Ki >1000 uM]

Drug as victim

Target	Modality	Activity	Metabolite
BCRP 545	substrate 3264 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209963Orig1s000ClinPharmR.pdf#page=27 Page: 27.0	no
OAT1 314	substrate 3264 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209963Orig1s000ClinPharmR.pdf#page=27 Page: 27.0	no
OAT3 328	substrate 3264 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209963Orig1s000ClinPharmR.pdf#page=27 Page: 27.0	no
OATP1B1 389	substrate 3264 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209963Orig1s000ClinPharmR.pdf#page=27 Page: 27.0	no
OATP1B3 333	substrate 3264 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209963Orig1s000ClinPharmR.pdf#page=27 Page: 27.0	no
OCT2 336	substrate 3264 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209963Orig1s000ClinPharmR.pdf#page=27 Page: 27.0	no
P-gp 1491	substrate 3264 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209963Orig1s000ClinPharmR.pdf#page=27 Page: 27.0	no
CES2 24	substrate 3264 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209963lbl.pdf#page=12 Page: 12.0	yes
CYP3A4 1670	substrate 3264 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209963lbl.pdf#page=12 Page: 12.0	yes
P-gp 1491	substrate 3264 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209963Orig1s000ClinPharmR.pdf#page=27 Page: 27.0	yes	BE 4

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 1603	inhibitor 1584 Sources: https://pubmed.ncbi.nlm.nih.gov/11561083/

Sourcing

Vendor/Aggregator	ID	URL
ABI Chem	AC1L9JBL
Alfa Chemistry	ACM53214
Aurora Fine Chemicals LLC	A17.902.496	http://online.aurorafinechemicals.com/info?ID=A17.902.496
ChemMol	30107819	http://www.chemmol.com/chemmol/30107819.html
ChemMol	99097714	http://www.chemmol.com/chemmol/99097714.html
Chemieliva Pharmaceutical Co., Ltd	PBCM0602073
Compound Cloud	122142
Compound Cloud	23724835
Compound Cloud	446220
Hangzhou Yuhao Chemical Technology	RT7155
LGC Standards	LGCAMP1345.05-11	https://www.lgcstandards.com/US/en/p/LGCAMP1345.05-11
LGC Standards	LGCAMP1345.05-12	https://www.lgcstandards.com/US/en/p/LGCAMP1345.05-12
LGC Standards	LGCFOR1345.05	https://www.lgcstandards.com/US/en/p/LGCFOR1345.05
NovoSeek	446220
Sigma Aldrich	1143008\|USP
Sigma Aldrich	19330\|SIAL
Sigma Aldrich	51621\|SIAL
Sigma Aldrich	C-008\|CERILLIAN
Sigma Aldrich	C1528\|SIAL
Sigma-Aldrich	C-008_CERILLIAN	https://www.sigmaaldrich.com/catalog/product/cerillian/c008?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	C8912_SIGMA	https://www.sigmaaldrich.com/catalog/product/sigma/c8912?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Smolecule	S524154	http://www.smolecule.com/products/s524154
THE BioTek	bt-264235	https://www.thebiotek.com/product/inhibitors/bt-264235
Tetrahedron	TS78461
Tocris	2833
Toronto Research Chemicals	A634018
Toronto Research Chemicals	C633500
Yick-Vic Chemicals & Pharmaceuticals (HK) Ltd.	CC-1775E
Yick-Vic Chemicals & Pharmaceuticals (HK) Ltd.	PH-0777
ZINC	ZINC000003875336	http://zinc15.docking.org/substances/ZINC000003875336

PubMed

Title	Date	PubMed
Antiglomerular basement membrane antibody-mediated glomerulonephritis after intranasal cocaine use.	1999	10095180
Sequential neuromotor examination in children with intrauterine cocaine/polydrug exposure.	1999 Apr	10355807
RGS mRNA expression in rat striatum: modulation by dopamine receptors and effects of repeated amphetamine administration.	1999 Apr	10098858
Role of cocaethylene in toxic symptoms due to repeated subcutaneous cocaine administration modified by oral doses of ethanol.	1999 Aug	10478337
Sex and menstrual cycle differences in the subjective effects from smoked cocaine in humans.	1999 Aug	10472516
Brief report: frequency of maternal cocaine use during pregnancy and infant neurobehavioral outcome.	1999 Dec	10608102
Comparative effects of sodium bicarbonate and sodium chloride on reversing cocaine-induced changes in the electrocardiogram.	1999 Dec	10598131
Effects of AMPA/kainate glutamate receptor antagonists on cocaine-induced convulsions and lethality in mice.	1999 Dec 15	10618468
Gender differences in treatment-seeking cocaine abusers--implications for treatment and prognosis.	1999 Fall	10598213
Selective inhibition of cocaine-seeking behaviour by a partial dopamine D3 receptor agonist.	1999 Jul 22	10432116
Antisocial personality disorder and psychopathy in cocaine-dependent women.	1999 Jun	10360122
Effects of contingent and non-contingent cocaine on drug-seeking behavior measured using a second-order schedule of cocaine reinforcement in rats.	1999 Jun	10327424
[Centrofacial necrosis secondary to cocaine use].	1999 Jun-Jul	10491482
Acute ischaemic colitis following intravenous cocaine use.	1999 May	10425576
Anticonvulsant efficacy of N-methyl-D-aspartate antagonists against convulsions induced by cocaine.	1999 May	10215643
Chronic inhaled cocaine abuse may predispose to the development of pancreatic adenocarcinoma.	1999 Nov	10612544
The effects of cocaine on mood and sleep in cocaine-dependent males.	1999 Nov	10609968
Serotonin(2C) receptors appear to mediate genetic sensitivity to cocaine-induced convulsions.	1999 Oct	10541732
Prenatal cocaine and neuromotor outcome at four months: effect of duration of exposure.	1999 Oct	10533991
Cocaine-induced erythrocytosis and increase in von Willebrand factor: evidence for drug-related blood doping and prothrombotic effects.	1999 Sep 13	10493323
Cocaine-induced mood disorder: prevalence rates and psychiatric symptoms in an outpatient cocaine-dependent sample.	1999 Spring	10365197
Effects of prenatal cocaine/crack and other drug exposure on electroencephalographic sleep studies at birth and one year.	2000 Jan	10617702
Cocaine induces apoptosis in fetal myocardial cells through a mitochondria-dependent pathway.	2000 Jan	10604926

Patents

Sample Use Guides

In Vivo Use Guide

Cocaine HCl 10% topical solution, up to 4 mL, is applied for 20 minutes via cotton pledget(s)

Route of Administration: Topical

In Vitro Use Guide

Neuronal cultures were prepared from 18-day-old Sprague–Dawley rat fetuses. Cultures were used for neurotoxicity experiments after 12 days in culture. To assess any toxic effects of cocaine per se, 10 mL aliquots of three different dilutions of the cocaine stock solution (0.1–10 mM final concentration in the medium) were added to cell cultures. Appropriate vehicle controls (same volume of solvent added) were included for each group.

Substance Class	Chemical Created by `admin` on `Fri Dec 16 16:36:46 UTC 2022` Edited by `admin` on `Fri Dec 16 16:36:46 UTC 2022`
Record UNII	I5Y540LHVR
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

COCAINE

Common Name

English

Cocaine [WHO-DD]

Common Name

English

COCAINE [VANDF]

Common Name

English

RX-0041

Code

English

RX0041

Code

English

(R)-(-)-COCAINE

Common Name

English

COCAINE [MI]

Common Name

English

COCAINUM [HPUS]

Common Name

English

8-AZABICYCLO(3.2.1)OCTANE-2-CARBOXYLIC ACID, 3-(BENZOYLOXY)-8-METHYL-, METHYL ESTER, (1R-(EXO,EXO))-

Common Name

English

METHYL (1R,2R,3S,5S)-3-(BENZOYLOXY)-8-METHYL-8-AZABICYCLO(3.2.1) OCTANE-2-CARBOXYLATE

Systematic Name

English

NEUROCAINE

Common Name

English

METHYL 3B-HYDROXY-1.ALPHA.H,5.ALPHA.H-TROPANE-2.BETA.-CARBOXYLATE BENZOATE (ESTER)

Common Name

English

3.BETA.-HYDROXY-2.BETA.-TROPANECARBOXYLIC ACID METHYL ESTER BENZOATE (ESTER)

Common Name

English

COCAINUM

Common Name

English

COCAINE [MART.]

Common Name

English

ECGONINE METHYL ESTER BENZOATE (ESTER)

Common Name

English

BENZOYLMETHYLECGONINE

Common Name

English

COCAINE [HSDB]

Common Name

English

IDS-NC-004

Code

English

COCAINE [USP MONOGRAPH]

Common Name

English

Classification Tree Code System Code

WHO-ATC

R02AD03